“Novavax, a Maryland biotechnology company that endured delays in developing a coronavirus vaccine, revealed results Monday showing that the world is close to having another shot that prevents illness and death, stops virus variants — and proves easy to store,” the Washington Post reports.
“The two-shot regimen was 90 percent effective at preventing people from falling ill in a 30,000-person trial conducted when variants had begun to complicate the pandemic in the United States and Mexico.”
Save to Favorites